Hypomelanotic Disorder Clinical Trials

Find Hypomelanotic Disorder Clinical Trials Near You

A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• The subject is able to communicate well with investigators, fully understands the purpose, nature, methods and potential adverse reactions of this trial, voluntarily participates as a study subject, comprehends and complies with all requirements of this research, and signs the Informed Consent Form (ICF) prior to initiation of any study procedures.

• At the time of ICF signature, the subject is aged ≥18 and ≤65 years old, with no restriction on gender.

• Clinically diagnosed with non-segmental vitiligo at screening.

• Subjects must meet the following criteria at screening and baseline:

• F-VASI ≥ 0.5 and T-VASI ≥ 5 at both screening and baseline; The disease is in progressive (active) phase or stable phase at screening and baseline.

• Progressive vitiligo: defined as appearance of new lesions or enlargement of existing lesions within the past 6 months (confirmed by photographs or medical records), or presence of confetti lesions, trichrome lesions, or Koebner phenomenon.

• Stable vitiligo: defined as absence of any signs of disease activity.

• The subject (and partner if applicable) agrees to avoid pregnancy and adopt effective contraceptive measures from ICF signature through 3 months after the last study drug administration.

⁃ Male subjects: must commit not to donate sperm during the study period and within 3 months after the last study medication.

⁃ Female subjects:

⁃ Women of childbearing potential: have a negative serum human chorionic gonadotropin (HCG) test at screening and are not breastfeeding.

⁃ Women without childbearing potential: have undergone permanent sterilization (e.g., bilateral oophorectomy, bilateral salpingectomy, hysterectomy), or are postmenopausal (defined as amenorrhea for more than 12 months excluding other pathological causes of amenorrhea; subjects under 60 years old must have serum follicle-stimulating hormone (FSH) \> 40 IU/L).

Locations
Other Locations
China
The First Hospital of China Medical University
RECRUITING
Shenyang
Contact Information
Primary
Li Qiang
qiang.li@enitiatebio.com
86-15957643460
Time Frame
Start Date: 2025-11-05
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 200
Treatments
Experimental: QY201 Tablets(5mg)
One tablet twice daily for 168 consecutive days
Experimental: QY201 Tablets(10mg)
One tablet twice daily for 168 consecutive days
Experimental: QY201 Tablets(20mg)
One tablet twice daily for 168 consecutive days
Placebo_comparator: QY201 Placebo Tablets
One tablet twice daily for 168 consecutive days
Related Therapeutic Areas
Sponsors
Leads: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

This content was sourced from clinicaltrials.gov